APA (7th ed.) Citation

S, S., P, T., VK, G., P, P., G, S., T, D., & D, S. (2025). Comparative cost-effectiveness of ribociclib and palbociclib as first-line treatment for HR+/HER2- advanced breast cancer in postmenopausal women: Analysis from a Medicare perspective. Journal of medical economics, 28(1), 2150. https://doi.org/10.1080/13696998.2025.2594952

Chicago Style (17th ed.) Citation

S, Sammons, Tarantino P, Gadi VK, Pathak P, Sopher G, Delea T, and Stellato D. "Comparative Cost-effectiveness of Ribociclib and Palbociclib as First-line Treatment for HR+/HER2- Advanced Breast Cancer in Postmenopausal Women: Analysis from a Medicare Perspective." Journal of Medical Economics 28, no. 1 (2025): 2150. https://doi.org/10.1080/13696998.2025.2594952.

MLA (9th ed.) Citation

S, Sammons, et al. "Comparative Cost-effectiveness of Ribociclib and Palbociclib as First-line Treatment for HR+/HER2- Advanced Breast Cancer in Postmenopausal Women: Analysis from a Medicare Perspective." Journal of Medical Economics, vol. 28, no. 1, 2025, p. 2150, https://doi.org/10.1080/13696998.2025.2594952.